Resona Asset Management Co. Ltd. Has $15.61 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Resona Asset Management Co. Ltd. decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 39,247 shares of the biopharmaceutical company’s stock after selling 2,250 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $15,614,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ALNY. Groupama Asset Managment lifted its holdings in Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after buying an additional 2,483,697 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after buying an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at $369,943,000. AQR Capital Management LLC lifted its holdings in Alnylam Pharmaceuticals by 295.2% in the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after buying an additional 555,759 shares during the period. Finally, Orbis Allan Gray Ltd lifted its holdings in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $298.48 on Thursday. The firm’s 50-day moving average price is $312.06 and its 200-day moving average price is $361.02. Alnylam Pharmaceuticals, Inc. has a 1-year low of $284.19 and a 1-year high of $495.55. The firm has a market capitalization of $39.85 billion, a P/E ratio of 81.55 and a beta of 0.31. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.44) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ALNY. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Chardan Capital reiterated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,598 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $523,584.70. Following the completion of the sale, the executive vice president directly owned 36,606 shares of the company’s stock, valued at $11,993,955.90. The trade was a 4.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total transaction of $567,538.50. Following the sale, the executive vice president directly owned 23,406 shares of the company’s stock, valued at approximately $7,483,834.44. The trade was a 7.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 21,255 shares of company stock valued at $6,930,337 over the last quarter. 0.86% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.